190 related articles for article (PubMed ID: 30319129)
1. [Radium 223 in castration resistant prostate cancer.].
Loizaga-Iriarte A; Camargo Ibargarai I; Senarriaga-Ruiz de la Illa N; Lacasa-Viscasillas I; Unda-Urzaiz M
Arch Esp Urol; 2018 Sep; 71(8):696-703. PubMed ID: 30319129
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
[TBL] [Abstract][Full Text] [Related]
3. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C
Prostate; 2016 Jul; 76(10):905-16. PubMed ID: 27004570
[TBL] [Abstract][Full Text] [Related]
5. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
[TBL] [Abstract][Full Text] [Related]
7. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
Shirley M; McCormack PL
Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
9. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Parker C; Zhan L; Cislo P; Reuning-Scherer J; Vogelzang NJ; Nilsson S; Sartor O; O'Sullivan JM; Coleman RE
Eur J Cancer; 2017 Jan; 71():1-6. PubMed ID: 27930924
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
[TBL] [Abstract][Full Text] [Related]
11. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
Shore ND
Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
[TBL] [Abstract][Full Text] [Related]
12. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Ryan CJ; Saylor PJ; Everly JJ; Sartor O
Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
[TBL] [Abstract][Full Text] [Related]
13. Practical guide to the use of radium 223 dichloride.
Den RB; Doyle LA; Knudsen KE
Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
[TBL] [Abstract][Full Text] [Related]
14. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
[TBL] [Abstract][Full Text] [Related]
15. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
16. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
18. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
19. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
Winter BM; von Rundstedt FC; Grimm MO
Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
[TBL] [Abstract][Full Text] [Related]
20. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
McNamara MA; George DJ
BMC Cancer; 2015 May; 15():371. PubMed ID: 25948240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
